Novoclem Appoints World Leading Experts in Cystic Fibrosis to Inaugural Scientific Advisory Board7/19/2017
Novoclem Appoints World Leading Experts in Cystic Fibrosis to Inaugural Scientific Advisory Board DURHAM, NC (July 19, 2017) Novoclem Therapeutics, Inc., a subsidiary of private life science technology company KNOW Bio, LLC, today announced the appointment of leading experts to its newly formed scientific advisory board. The SAB will serve as a strategic resource to Novoclem as it continues to develop multiple nitric oxide-releasing biopolymers for the treatment of severe respiratory diseases. “We are thrilled with the addition of these experts in cystic fibrosis, pediatrics and infectious disease to our team of advisors,” said Anne Whitaker, president and chief executive officer of Novoclem Therapeutics. “The knowledge and experience our SAB members bring to Novoclem is invaluable as we move our first product forward into clinical development next year. The SAB will also inform the development plan of additional new chemical entities within our discovery pipeline.” The inaugural members of Novoclem’s scientific advisory board include:
“The launch of Novoclem’s scientific advisory board underscores our commitment to continuing the development of novel inhaled nitric oxide-based therapeutics for the treatment of numerous respiratory diseases including cystic fibrosis,” said Mark Schoenfisch, Ph.D., Chief Scientific Officer of Novoclem. “The core of Novoclem’s commercialization efforts is our broadly applicable nitric oxide biopolymer platform that facilitates the development of inhaled antimicrobial, mucolytic and anti-inflammatory therapies. The addition of expert clinicians to our team further positions Novoclem to achieve our goal of leading a new fight for cystic fibrosis patients, enabling them to breathe better and live the life they desire.” About Novoclem Therapeutics Novoclem Therapeutics was created to develop nitric oxide therapies for cystic fibrosis and other respiratory diseases. It is initially focused on developing a treatment for severe bacterial lung infections in CF patients. The technology is effective against both antibiotic-resistant Pseudomonas aeruginosa, which is present in the lungs of approximately 60 percent of patients with CF, and Mycobacterium abscessus, a growing threat to CF patients. The company anticipates submitting an Investigational New Drug application and initiating First in Human clinical trials in 2018. More info available at vasttherapeutics.com About KNOW Bio LLC KNOW Bio, LLC was created to develop and optimize the company’s proprietary and versatile nitric oxide platform. The technology can be delivered as a drug in a variety of doses and release time frames, which makes the therapeutic areas that will likely be impacted by this platform immense. Forward-looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: risks associated with the drug development process; reliance on key personnel; the early stage of our business; competition; and other risks described in other Company press releases and presentations. KNOW Bio and Novoclem Therapeutics assumes no obligation and does not intend to update these forward-looking statements, except as required by law. Comments are closed.
|
|
RSS Feed
|
AddressContact Us
|
|
Copyright © 2021 Vast Therapeutics - All Rights Reserved